Vahid Bahrambeigi

Vahid Bahrambeigi

Auto-generated profile, based on publicly available information

Vahid Bahrambeigi

Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, Texas

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JDJulien Dilly
Julien Dilly
MHMegan T. Hoffman
Megan T. Hoffman
LALaleh Abbassi
Laleh Abbassi
ZLZiyue Li
Ziyue Li
FPfrancesca Paradiso
francesca Paradiso
AAAndrew J. Aguirre
Andrew J. Aguirre
KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC); however, resistance is common. Among patients with KRASG12C-mutant PDAC treated with adagrasib or sotorasib, mutations in PIK3CA and KRAS, and amplifications of KRASG12C, MYC, MET, EGFR, and CDK6 emerged at acquired resistance. In PDAC cell lines and organoid models treated with the KRASG12D inhibitor MRTX1133, epithelial-to-mesenchymal transition and PI3K-AKT-mTOR signaling associate with resistance to therapy. MRTX1133 treatment of the KrasLSL-G12D/+; Trp53LSL-R172H/+; p48-Cre (KPC) mouse model yielded deep tumor regressions, but drug resistance ultimately emerged, accompanied by amplifications of Kras, Yap1, Myc, Cdk6, and Abcb1a/b, and co-evolution of drug-resistant transcriptional programs. Moreover, in KPC and PDX models, mesenchymal and basal-like cell states displayed increased response to KRAS inhibition compared to the classical state. Combination treatment with KRASG12D inhibition and chemotherapy significantly improved tumor control in PDAC mouse models. Collectively, these data elucidate co-evolving resistance mechanisms to KRAS inhibition and support multiple combination therapy strategies. Significance: Acquired resistance may limit the impact of KRAS inhibition in patients with PDAC. Using clinical samples and multiple preclinical models, we define heterogeneous genetic and non-genetic mechanisms of resistance to KRAS inhibition that may guide combination therapy approaches to improve the efficacy and durability of these promising therapies for patients. See related commentary by Marasco and Misale, p. 2018

26 April 2018 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
EKEnder Karaca
Ender Karaca
JPJennifer E. Posey
Jennifer E. Posey
ZAZeynep Coban Akdemir
Zeynep Coban Akdemir
DPDavut Pehlivan
Davut Pehlivan
THTamar Harel
Tamar Harel
JLJames Lupski
James Lupski

1 January 2018 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
JWJanson J. White
Janson J. White
JMJuliana F. Mazzeu
Juliana F. Mazzeu
ZCZeynep Coban-Akdemir
Zeynep Coban-Akdemir
YBYavuz Bayram
Yavuz Bayram
VBVahid Bahrambeigi
Vahid Bahrambeigi
CCClaudia M.B. Carvalho
Claudia M.B. Carvalho

14 December 2016 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
TGTomasz Gambin
Tomasz Gambin
ZAZeynep C. Akdemir
Zeynep C. Akdemir
BYBo Yuan
Bo Yuan
SGShen Gu
Shen Gu
TCTheodore Chiang
Theodore Chiang
JLJames Lupski
James Lupski
We developed an algorithm, HMZDelFinder, that uses whole exome sequencing (WES) data to identify rare and intragenic homozygous and hemizygous (HMZ) deletions that may represent complete loss-of-function of the indicated gene. HMZDelFinder was applied to 4866 samples in the Baylor–Hopkins Center for Mendelian Genomics (BHCMG) cohort and detected 773 HMZ deletion calls (567 homozygous or 206 hemizygous) with an estimated sensitivity of 86.5% (82% for single-exonic and 88% for multi-exonic calls) and precision of 78% (53% single-exonic and 96% for multi-exonic calls). Out of 773 HMZDelFinder-detected deletion calls, 82 were subjected to array comparative genomic hybridization (aCGH) and/or breakpoint PCR and 64 were confirmed. These include 18 single-exon deletions out of which 8 were exclusively detected by HMZDelFinder and not by any of seven other CNV detection tools examined. Further investigation of the 64 validated deletion calls revealed at least 15 pathogenic HMZ deletions. Of those, 7 accounted for 17–50% of pathogenic CNVs in different disease cohorts where 7.1–11% of the molecular diagnosis solved rate was attributed to CNVs. In summary, we present an algorithm to detect rare, intragenic, single-exon deletion CNVs using WES data; this tool can be useful for disease gene discovery efforts and clinical WES analyses.

9 December 2019 in Genome Medicine
Verified
Journal Article
Open access
PDF file
VBVahid Bahrambeigi
Vahid Bahrambeigi
XSXiaofei Song
Xiaofei Song
KSKaren Sperle
Karen Sperle
CBChristine R. Beck
Christine R. Beck
HHHadia Hijazi
Hadia Hijazi
JLJames Lupski
James Lupski
Background: We investigated the features of the genomic rearrangements in a cohort of 50 male individuals with proteolipid protein 1 (PLP1) copy number gain events who were ascertained with Pelizaeus-Merzbacher disease (PMD; MIM: 312080). We then compared our new data to previous structural variant mutagenesis studies involving the Xq22 region of the human genome. The aggregate data from 159 sequenced join-points (discontinuous sequences in the reference genome that are joined during the rearrangement process) were studied. Analysis of these data from 150 individuals enabled the spectrum and relative distribution of the underlying genomic mutational signatures to be delineated. Methods: Genomic rearrangements in PMD individuals with PLP1 copy number gain events were investigated by high-density customized array or clinical chromosomal microarray analysis and breakpoint junction sequence analysis. Results: High-density customized array showed that the majority of cases (33/50; ~ 66%) present with single duplications, although complex genomic rearrangements (CGRs) are also frequent (17/50; ~ 34%). Breakpoint mapping to nucleotide resolution revealed further previously unknown structural and sequence complexities, even in single duplications. Meta-analysis of all studied rearrangements that occur at the PLP1 locus showed that single duplications were found in ~ 54% of individuals and that, among all CGR cases, triplication flanked by duplications is the most frequent CGR array CGH pattern observed. Importantly, in ~ 32% of join-points, there is evidence for a mutational signature of microhomeology (highly similar yet imperfect sequence matches). Conclusions: These data reveal a high frequency of CGRs at the PLP1 locus and support the assertion that replication-based mechanisms are prominent contributors to the formation of CGRs at Xq22. We propose that microhomeology can facilitate template switching, by stabilizing strand annealing of the primer using W-C base complementarity, and is a mutational signature for replicative repair.

7 March 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
VBVahid Bahrambeigi
Vahid Bahrambeigi
JLJaewon Lee
Jaewon Lee
VBVittorio Branchi
Vittorio Branchi
KRKimal I. Rajapakshe
Kimal I. Rajapakshe
ZXZhichao Xu
Zhichao Xu
PGPaola A. Guerrero
Paola A. Guerrero
Longitudinal monitoring of patients with advanced cancers is crucial to evaluate both disease burden and treatment response. Current liquid biopsy approaches mostly rely on the detection of DNA-based biomarkers. However, plasma RNA analysis can unleash tremendous opportunities for tumor state interrogation and molecular subtyping. Through the application of deep learning algorithms to the deconvolved transcriptomes of RNA within plasma extracellular vesicles (evRNA), we successfully predicted consensus molecular subtypes in patients with metastatic colorectal cancer. Analysis of plasma evRNA also enabled monitoring of changes in transcriptomic subtype under treatment selection pressure and identification of molecular pathways associated with recurrence. This approach also revealed expressed gene fusions and neoepitopes from evRNA. These results demonstrate the feasibility of using transcriptomic-based liquid biopsy platforms for precision oncology approaches, spanning from the longitudinal monitoring of tumor subtype changes to the identification of expressed fusions and neoantigens as cancer-specific therapeutic targets, sans the need for tissue-based sampling. Significance: The development of an approach to interrogate molecular subtypes, cancer-associated pathways, and differentially expressed genes through RNA sequencing of plasma extracellular vesicles lays the foundation for liquid biopsy–based longitudinal monitoring of patient tumor transcriptomes.